CONTRACEPTIVE COMPOSITIONS CONTAINING CYCLIC CARBAMATES AND AMIDE DERIVATIVES

Abstract: This invention relates to cyclic combination therapies and regimens utilizing, in combination with progestins, estrogens, or both, substituted indoline derivative compounds which are antagonists of the progesterone receptor having general structure (I) wherein A and B are independent substituents selected from S, CH or N; provided that when A is S, B is CH or N; and when B is S, A is CH or N; and A and B cannot both be CH; and when A and B both equal N, one N may be optionally substituted with a C1 to C6 alkyl group; R1 and R2 are independent substituents selected from the group of H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C2 to C6 alkenyl, substituted C2 to C6 alkenyl, C2 to C6 alkynyl, substituted C2 to C6 alkynyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR<A>, or NR<B>COR<A>; or R<1> and R<2> are fused to form optionally substituted 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic ring, the heterocyclic ring containing one to three heteroatoms selected from the group of O, S and N; or pharmaceutically useful salts thereof. These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minimization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.

Description: CONTRACEPTIVE COMPOSITIONS CONTAINING CYCLIC CARBAMATES AND AMIDE DERIVATIVES Field of the Invention 5 This invention relates to regimens of administering compounds which are antagonists of the progesterone receptor in combination with a progestin, an estrogen, or both Background of the Invention 10 Intracellular receptors (IR) form a class of structurally related genetic regulators known as "hgand dependent transcription factors" (R M Evans, Science, 240, 889, 1988) The steroid receptor family is a subset of the IR family, including progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR) 15 The natural hormone, or hgand, for the PR is the steroid progesterone, but synthetic compounds, such as medroxyprogesterone acetate or levonorgestrel, have been made which also serve as kgands Once a hgand is present in the fluid surrounding a cell, it passes through the membrane via passive diffusion, and binds to the IR to create a receptor/ligand complex This complex then translocates to the 20 nucleus of the cell where it binds to a specific gene or genes present in the cell's DNA Once bound to a specific DNA sequence the complex modulates the production of the mRNA and protein encoded by that gene A compound that binds to an IR and mimics the action of the natural hormone is termed an agonist, whilst a compound which inhibits the effect of the hormone is an 25 antagonist PR agonists (natural and synthetic) are known to play an important role in the health of women PR agonists are used in birth control formulations, typically in the presence of an ER agonist ER agonists are used to treat the symptoms of menopause, but have been associated with a prohferative effect on the uterus (in non- hysterectomized women) which can lead to an increased nsk of uterine cancers Co- administration of a PR agonist reduces/ablates that risk PR antagonists may also be used in contraception In this context they may be administered alone (Ulmann, et al, Ann N Y Acad Sci , 261, 248, 1995), in combination with a PR agonist (Kekkonen. et al, Fertility and Sterility, 60, 610, 1993) or in combination with a partial ER antagonist such as tamoxifen (WO 96/19997 Al , July 4, 1996) PR antagonists may also be useful for the treatment of hormone dependent breast cancers (Horwitz, et al, Horm Cancer, 283, pub Birkhaeuser, Boston, Mass , ed Nedeckis) as well as uterine and ovarian cancers PR antagonists may also be useful for the treatment of non-malignant chronic conditions such as fibroids (Murph> , et al, J Chn Endo Metab , 76, 513, 1993) and endometriosis (Kettel, et al, Fertility and Sterility, 56, 402, 1991) PR antagonists may also be useful in hormone replacement therapy for post menopausal patients in combination with a partial ER antagonist such as tamoxifen (US 5719136) PR antagonists such as Mifepπstone have also been shown to have bone sparing effects in rodents, and as such may be useful in the treatment of osteoporosis associated with the menopause (Barengolts, et al, Bone, 17, 21, 1995) PR antagonists, such as mifepπstone and onapπstone, have been shown to be effective in a model of hormone dependent prostate cancer, which may indicate their utility in the treatment of this condition in men (Michna, et al, Ann N Y Acad Sci , 761, 224, 1995) Jones, et al, (U S Patent No 5,688,810) described the PR antagonist dihydroquinoline 1 Jones, et al, described the enol ether 2 (U.S. Patent No. 5,693,646) as a PR hgand. Jones, et al, described compound 3 (U.S Patent No. 5,696,127) as a PR ligand Zhi. et al, described lactones 4, 5 and 6 as PR antagonists (J. Med. Chem . 41, 291. 1998) Zhi, et al, described the ether 7 as a PR antagonist (J Med Chem, 41, 291. 1998) Combs, et al , disclosed the amide 8 as a ligand for the PR (J Med Chem , 38, 4880, 1995) Perlman, et al . described the vitamin D analog 9 as a PR ligand (7et Letters, , 2295, 1994) Hamann, et al, described the PR antagonist 10 (Ann N Y Acad Sci , 761, 383, 5) 10 Chen, et al, descπbed the PR antagonist 11 (Chen, et al, POI-37, 16 th Int Cong Het Chem , Montana. 1997) 11 Kurihaπ, et al , descπbed the PR hgand 12 (J Antibiotics, 50, 360, 1997) 12 U S Patent No 5,521,166 (Grubb) teaches cyclo phasic hormonal regimens comprising an antiprogestin and a progestin wherein the progestin is administered in the alternating presence and absence of an antiprogestin The disclosed regimens also provide for use of an estrogen for a period of from 2-4 days to prevent breakthrough bleeding Description of the Invention. This invention provides combination therapies and dosing regimens utilizing antiprogestational agents in combination with one or more progestational agents This invention further provides methods of treatment and dosing regimens further utilizing in combination with these antiprogestins and progestins, an estrogen, such as ethinyl estradiol These regimens and combinations may be administered to a mammal to induce contraception or for the treatment and/or prevention of secondary amenorrhea. dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometπum, ovary, breast, colon, prostate Additional uses of the invention include stimulation of food intake The uses herein for the treatment and/or prevention of the conditions or diseases descπbed above includes the continuous administration or periodic discontinuation of administration of the invention to allow for minimization of effect dose or minimization of side effects or cyclic menstrual bleeding The use of this invention for contraception includes administration, preferably orally, to a female of child bearing age an antiprogestin in combination with an estrogen or progestin or both These administration regimens are preferably carried out over 28 consecutive days, with a terminal portion of the cycle containing administration of no progestins, estrogens or anti-progestins The progestins of these combinations may be administered alone or in combination with an estrogen for the first 14 to 24 days of the cycle, the progestins being administered at a dosage range equal in progestational activity to about 35 μg to about 150 μg levonorgestrel per day, preferably equal in activity to from about 35 μg to about 100 μg levonorgestrel per day An antiprogestin may then be administered alone or in combination with an estrogen for a period of 1 to 11 days to begin on an> cycle day between day 14 and 24 The anti-pro gestin in these combinations may be administered at a dose of from about 2μg to about 50 μg per day and the estrogen may be administered at a dose of from about 10 μg to about 35 μg per day In an oral administration, a package or kit containing 28 tablets will include a placebo tablet on those days when the antiprogestin or progestin or estrogen is not administered In a preferred embodiment of this invention, the progestins of this invention may be administered alone or in combination with estrogen for the initial 18 to 21 days of a 28-day cycle, followed by administration of an antiprogestin, alone or in combination with an estrogen, for from 1 to 7 days The estrogen to be used in the combinations and formulations of this invention is preferably ethinyl estradiol Progestational agents useful with this invention include, but are not limited to, levonorgestrel, norgestrel, desogestrel, 3-ketodesogestrel, norethindrone, gestodene. norethindrone acetate, norgestimate, osaterone, cyproterone acetate, tnmegestone. dienogest, drospirenone, nomegestrol, or (17-deacetyl)norgestιmate Among the preferred progestins for use in the combinations of this invention are levonorgestrel, gestodene and tnmegestone Examples of orally administered regimens of this invention over a 28 day cycle include administration of a progestational agent solely for the first 21 days at a daily dose equal in progestational activity to from about 35 to about 100 μg of levonorgestrel An antiprogestin compound of this invention may then be administered at a daily dose of from about 2 to 50 mg from day 22 to day 24, followed by no administration or administration of a placebo for days 25 to 28 It is most preferred that the daily dosages of each relevant active ingredient be incorporated into a combined, single daily dosage unit, totaling 28 daily units per 28-day cycle In another regimen, a progestational agent may be coadministered for the first 21 days at a daily dose equal in progestational activity to from about 35 to about 150 μg levonorgestrel, preferably equal in activity to from about 35 to about 100 μg levonorgestrel, with an estrogen, such as ethinyl estradiol, at a daily dose range of from about 10 to about 35 μg This may be followed as descπbed above with an antiprogestin administered at a daily dose of from about 2 to 50 mg from da\ 22 to da 24, followed by no administration or administration of a placebo for days 25 to 28 Still another regimen within the scope of this invention will include coadministration from days 1 to 21 of a progestational agent, the progestational agent, preferably levonorgestrel, being administered at a daily dose equal in progestational activity to from about 35 to about 100 μg levonorgestrel, and an estrogen, such as ethinyl estradiol, at a daily dose range of from about 10 to about 35 μg This will be followed on days 22 to 24 by coadministration of an antiprogestin (2 to 50 mg/day) and an estrogen, such as ethinyl estradiol, at a daily dose of from about 10 to about 35 μg From day 25 to day 28, this regimen may be followed by no administration or administration of a placebo This invention also kits or packages of pharmaceutical formulations designed for use in the regimens descnbed herein These kits are preferably designed for daily oral administration over a 28-day cycle, preferably for one oral administration per day, and organized so as to indicate a single oral formulation or combination of oral formulations to be taken on each day of the 28-day cycle Preferably each kit will include oral tablets to be taken on each the days specified, preferably one oral tablet will contain each of the combined daily dosages indicated According to the regimens described above, one 28-day kit may compπse a) an initial phase of from 14 to 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel, preferably equal in progestational activity to about 35 to about 100 μg levonorgestrel, b) a second phase of from 1 to 11 daily dosage units of an antiprogestin compound of this invention, each daily dosage unit containing an antiprogestin compound at a daily dosage of from about 2 to 50 mg, and c) optionally, a third phase of an orally and pharmaceutically acceptable placebo for the remaining days of the cycle in which no antiprogestin, progestin or estrogen is administered A preferred embodiment of this kit may comprise a) an initial phase of 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel, preferabl> equal in progestational activity to about 35 to about 100 μg levonorgestrel. b) a second phase of 3 daily dosage units for days 22 to 24 of an antiprogestin compound of this invention, each daily dosage unit containing an antiprogestin compound at a daily dosage of from about 2 to 50 mg, and c) optionally, a third phase of 4 daily units of an orally and pharmaceutically acceptable placebo for each of days 25 to 28 Another 28-day cycle packaging regimen or kit of this invention compπses a) a first phase of from 18 to 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel, preferably equal in activity to from about 35 to about 100 μg levonorgestrel, and, as an estrogen, ethinyl estradiol at a daily dose range of from about 10 to about 35 μg, and b) a second phase of from 1 to 7 daily dosage units of an antiprogestin of this invention at a daily dose of from about 2 to 50 mg, and c) optionally, an orally and pharmaceutically acceptable placebo for each of the remaining 0-9 days in the 28-day cycle in which no progestational agent, estrogen or antiprogestin is administered A preferred embodiment of the kit descπbed above may compπse a) a first phase of 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel, preferably equal in activity to from about 35 to about 100 μg levonorgestrel, and, as an estrogen ethinyl estradiol at a daily dose range of from about 10 to about 35 μg, and b) a second phase of 3 daily dosage units for days 22 to 24 of an antiprogestin administered at a daily dose of from about 2 to 50 mg, and c) optionally, a third phase of 4 daily dose units of an orally and pharmaceutically acceptable placebo for each of days 25 to 28 A further 28-day packaged regimen or kit of this invention comprises a) a first phase of from 18 to 21 daily dosage units, each containing a progestational agent of this invention at a daily dose equal in progestational activity to about 35 to about 150 μg levonorgestrel, preferably equal in activity to from about 35 to about 100 μg levonorgestrel, and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg, b) a second phase of from 1 to 7 daily dose units, each daily dose unit containing an antiprogestin of this invention at a concentration of from 2 to 50 mg, and ethinyl estradiol at a concentration of from about 10 to about 35 μg, and c) optionally, an orally and pharmaceutically acceptable placebo for each of the remaining 0-9 days in the 28-day cycle in which no progestational agent, estrogen or antiprogestin is administered A prefeπed embodiment of the package or kit just descπbed compπses a) a first phase of 21 daily dosage units, each containing a progestational agent of this invention at a daily dose equal in progestational activity to about 35 to about 150 μg levonorgestrel, preferably from about 35 to about 100 μg levonorgestrel, and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg, b) a second phase of 3 daily dose units for days 22 to 24, each dose unit containing an antiprogestin of this invention at a concentration of from 2 to 50 mg, and ethinyl estradiol at a concentration of from about 10 to about 35 μg, and c) optionally, a third phase of 4 daily units of an orally and pharmaceutically acceptable placebo for each of days 25 to 28 In each of the regimens and kits just descπbed, it is preferred that the daily dosage of each pharmaceutically active component of the regimen remain fixed in each particular phase in which it is administered It is also understood that the daily dose units described are to be administered in the order described, with the first phase followed in order by the second and third phases To help facilitate compliance with each regimen, it is also preferred that the kits contain the placebo described for the final days of the cycle It is further preferred that each package or kit comprise a pharmaceutically acceptable package having indicators for each day of the 28-dav cycle, such as a labeled blister package or dial dispenser packages known in the art In this disclosure, the terms anti-progestational agents, anti-progestins and progesterone receptor antagonists are understood to be synonymous Similarly, progestins, progestational agents and progesterone receptor agonists are understood to refer to compounds of the same activity These dosage regimens may be adjusted to provide the optimal therapeutic response For example, several divided doses of each component may be administered daily or the dose may be proportionally increased or reduced as indicated by the exigencies of the therapeutic situation In the descriptions herein, reference to a daily dosage umt may also include divided units which are administered over the course of each day of the cycle contemplated Compounds of this invention which may be used as the anti-progestational agents in the kits, methods and regimens herein include those of the Formula 1 wherein A and B are independent substituents selected from S. CH or N, Provided that when A is S, B is CH or N, provided that and A and B cannot both be CH, and when A and B both equal N, one N may be optionally substituted with an Ci to C 6 alkyl group, Ri and R 2 are independent substituents selected from the group of H, Ci to Cβ alkyl, substituted Ci to Cβ alkyl, C 2 to Cβ alkenyl, substituted C 2 to Cβ alkenyl, C 2 to C 6 alkynyl, substituted C to C 6 alkynyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR A , or NR B COR A , or R 1 and R 2 are fused to form a) an optionally substituted 3 to 8 membered spirocyclic alkyl ring, preferably a 3 to 6 membered spirocyclic alkyl πng, or b) an optionally substituted 3 to 8 membered spirocyclic alkenyl πng, preferably a 3 to 6 membered spirocyclic alkenyl πng, or c) an optionally substituted 3 to 8 membered spirocyclic ring containing one to three heteroatoms selected from O, S and N, preferably a 3 to 6 membered spirocyclic πng containing one to three heteroatoms, R A is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted C to C 3 alkoxy, C_ to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl, R B is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl, R 3 is H, OH, NH 2 , Cj to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 6 alkenyl, substituted Ci to C 6 alkenyl, alkynyl, or substituted alkynyl, or COR c , R c is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted C to C 3 alkoxy. to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl, R 4 is a tπsubstituted benzene πng containing the substituents X, Y and Z as shown below, X is selected from halogen, CN, Cj to C, alkyl, substituted Ci to C-, alkyl, d to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 thioalkyl, substituted C_ to C 3 thioalkyl, Ci to C 3 aminoalkyl. substituted Ci to C^ aminoalkyl, N0 2 , Ci to C 3 perfluoro alkyl, 5 or 6 membered heterocyclic πng containing 1 to 3 heteroatoms, COR D , OCOR D , or NR E COR D , R D is H, Ci to C 3 alkyl, substituted Cj to C 3 alkyl, aryl, substituted aryl, C to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted C t to C 3 aminoalkyl, R E is H, Ci to C 3 alkyl, or substituted Cj to C 3 alkyl, Y and Z are independent independently selected from H, halogen, CN, N0 2 , Cj to C 3 alkoxy, Ci to C 3 alkyl, or d to C 3 thioalkyl, or R 4 is a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O S, SO, S0 2 or NR 5 and containing one or two independent substituents from the group including H, halogen, CN, N0 2 and Ci to C 3 alkyl, Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, COR F , or NR G COR F , R F is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy. substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl, R G is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl, R 5 is H, or Ci to C 3 alkyl, W is O or a chemical bond or a pharmaceutically acceptable salt thereof Among the prefeπed anti-pro gestational compounds for use with this invention are those of Formula I wherein A and B are independent substituents S, CH or N, provided that when A is S, B is CH or N, and when B is S, A is CH or N, and A and B cannot both be CH, and when A and B both equal N, one N may be optionally substituted with an Ci to Cβ alkyl group, R 1 is H, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, CO R A , or NR B COR A , R 2 is H, C] to C 6 alkyl, substituted C l to C 6 alkyl, C 2 to C 6 alkenyl, substituted C 2 to C 6 alkenyl, C 2 to Cβ alkynyl, substituted C 2 to C 6 alkynyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl. heterocyclic, substituted heterocyclic, COR A , or NR B COR A , or R 1 and R 2 are fused to form a) an optionally substituted 3 to 8 membered spirocyclic alkyl πng, or b) an optionally substituted 3 to 8 membered spirocyclic alkenyl πng, or c) an optionally substituted 3 to 8 membered spirocyclic ring containing one to three heteroatoms selected from the group of O, S and N, R A is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl. or substituted Ci to C 3 aminoalkyl, R B is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl, R 3 is H, OH, NH 2 , Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 6 alkenyl, substituted Ci to C O alkenyl. alkynyl. or substituted alkynyl. or COR c , R c is H, Ci to C 4 alkyl, substituted Ci to C 4 alkyl, aryl, substituted ar\l Ci to C alkoxy, substituted Ci to C 4 alkoxy, Ci to C aminoalkyl, or substituted Ci to C aminoalkyl. R 4 is a tπsubstituted benzene ring containing the substituents X, Y and Z as shown below X is taken from the group including halogen, CN, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 thioalkyl, substituted Ci to C 3 thioalkyl, Ci to C 3 aminoalkyl, substituted Ci to C 3 aminoalkyl, N0 2 , Ci to C 3 perfluoroalkyl, 5-membered heterocychc ring containing 1 to 3 heteroatoms, COR D , OCOR D , or NR E COR D , R D is H, Ci to C alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl, R E is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl, Y and Z are independent substituents taken from the group including H, halogen, CN, N0 2 , Ci to C 3 alkoxy, C λ to C 3 alkyl, or Ci to C 3 thioalkyl, or R 4 is a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O S, SO, S0 2 or NR 5 and containing one or two independent substituents from the group including H, halogen, CN, N0 2 and Ci to C 3 alkyl, or Ci to C 3 alkoxy, R 5 is H or Ci to C 3 alkyl. W is O or a chemical bond or a pharmaceutically acceptable salt thereof Further preferred progesterone receptor antagonists are those of Formula I wherein A and B are independent substituents from the group including S, CH or N, provided that when A is S. B is CH or N, and when B is S, A is CH or N. and A and B cannot both be CH, R 1 = R 2 and are selected from the group which includes Ci to C 3 alkyl, substituted Ci to C 3 alkyl, or spirocyclic alkyl constructed by fusing R 1 and R 2 to form a 3 to 6 membered spirocyclic πng, R 3 is H, OH, NH 2 , Ci to C 6 alkyl, substituted Ci to C 6 alkyl, or COR c , R c is H, Ci to C 4 alkyl, or d to C 4 alkoxy, R 4 is a disubstituted benzene πng containing the substituents X and Y as shown below X is selected from the group including halogen, CN, Ci to C 3 alkoxy, Ci to C 3 alkyl, N0 2 , Ci to C 3 perfluoroalkyl, 5 membered heterocychc ring containing 1 to 3 heteroatoms, or Ci to C 3 thioalkyl. Y is a substituent on the 4' or 5' position selected from the group of H, halogen, CN, N0 2 , Ci to C 3 alkoxy, to C 4 alkyl, or Ci to C 3 thioalkyl, or R is a five membered πng with the structure shown below R 5 is H, or Ci to C 3 alkyl, or Ci to C 4 C0 2 alkyl, X' is selected from halogen, CN, N0 2 , Ci to C 3 alkyl or Ci to d alkoxy, li Y' is H or Ci to C 4 alkyl, or R 4 is a six membered πng with the structure X 2 is halogen, CN or N0 2 , W is O or a chemical bond, or a pharmaceutically acceptable salt thereof The anti-pro gestational compounds of this invention may contain an asymmetnc carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers While shown without respect to stereochemistry in Formula I, II, and III, the present invention includes such optical isomers and diastereomers, as well as the racemic and resolved, enantiomeπcally pure R and S stereoisomers, as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof The term "alkyl" is used herein to refer to both straight- and branched-chain saturated aliphatic hydrocarbon groups having from one to 8 carbon atoms, preferably from 1 to 6 carbon atoms, "alkenyl" is intended to include both straight- and branched-chain alkyl group having from 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms, with at least one carbon-carbon double bond, "alkynyl" group is intended to cover both straight- and branched-chain alkyl group having from 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms, with at least one carbon-carbon triple bond The terms "substituted alkyl", "substituted alkenyl", and "substituted alkynyl" refer to alkyl. alkenyl, and alkynyl as just described having one or more substituents from the group including halogen, CN, OH. N0 2 . amino, aryl. heterocychc, substituted aryl, substituted heterocyc c, alkoxy, aryloxy. substituted alkyloxy, alkylcarbonyl, alkylcarboxy. alkylamino, arylthio These substituents may be attached to any carbon of alkyl, alkenyl, or alkynyl group provided that the attachment constitutes a stable chemical moiety The term "aryl" is used herein to refer to an aromatic system which may be a single πng or multiple aromatic rings fused or linked together as such that at least one part of the fused or linked rings forms the conjugated aromatic system. The aryl groups include but not limited to phenyl. naphthyl, biphenyl, anthryl, tetrohydronaphthyl, phenanthryl The term "substituted aryl" refers to aryl as just defined having one or more substituents from the group including halogen. CN, OH, N0 2 , amino. alkyl. cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio The term "heterocychc" is used herein to describe a stable 4- to 7-membered monocyc c or a stable multicychc heterocyc c ring which is saturated, partially unsaturated, or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group including N, O, and S atoms The N and S atoms may be oxidized The heterocyclic ring also includes any multicychc πng in which any of above defined heterocyc c rings is fused to an aryl ring The heterocychc rmg may be attached at any heteroatom or carbon atom provided the resultant structure is chemically stable Such heterocyclic groups include, for example, tetrahydrofuran. pipendinyl, piperazinyl, 2-oxopιpeπdιnyl. azepinyl, pyrrohdinyl, imidazolyl, pyridyl, pyrazinyl, pyπmidinyl, pyπdazinyl, oxazolyl, isoxazolyl, morpholinyl, indolyl. quinolinyl, thienyl, furyl, benzofuranyl, benzothienyl, thiamorpho nyl, thiamorpholinyl sulfoxide, and isoquinolinyl The term "substituted heterocychc" is used herein to describe the heterocyc c just defined having one or more substituents selected from the group which includes halogen, CN, OH, N0 2 . amino, alkyl, substituted alkyl, cycloalkyl, alkenyl. substituted alkenyl. alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy. alkylamino, or arylthio The term "alkox> " is used herein to refer to the OR group. where R is alkyl or substituted alkyl The term "aryloxy" is used herein to refer to the OR group, where R is aryl or substituted aryl The term "alkylcarbonyl" is used herein to refer to the RCO group, where R is alkyl or substituted alkyl The term "alkylcarboxy" is used herein to refer to the COOR group, where R is alkyl or substituted alkyl The term "aminoalkyl" refers to both secondary and tertiary amines wherein the alkyl or substituted alkyl groups may be either same or different and the point of attachment is on the nitrogen atom The term "thioalkyl" is used herein to refer to the SR group, where R is alkyl or substituted alkyl The term "halogen" refers to CI. Br, F, and I element The anti-pro gestin compounds of this invention can be prepared following the Schemes illustrated below CYCLOCARBAMATE DERIVATIVES Processes for preparing thiophene cyclocarbamate derivatives A. Methods for synthesizing the thiophene cyclocarbamate compounds depicted in Scheme 1 are described below R 4 CH 2 CHO 1 S, CNCH 2 C0 2 e, Et 3 N (Gewald Reaction) 4 S Scheme 1 Thus the amino thiophene ester 2 was prepared according to a literature procedure involving the Gewald reaction (see Comprehensive Heterocyclic Chemistry II A Review of the Literature 1982-1995 A R Katritsky et al Vol 2 page 639), 1 e the reaction of a suitably substituted aromatic acetaldehyde with sulfur and methyl cyanoacetate in refluxing methanol (Scheme 1) Reaction of the 2-amιno group with a suitable chloroformate or carbonate affords the protected amine 3 This can be accomphshed by allowing 2 to react with a chloroformate or carbonate deπvative such as methyl chloroformate, ethyl chloroformate, allyl chloroformate, 2- (trrmethylsiryl)ethyl chloroformate or di-tert-butyldicarbonate in a solvent such as benzene, toluene, xylene, dichloromethane, tetrahydrofuran or pyπdine The reaction can be carried out under an inert atmosphere (nitrogen or argon) from 0°C up to the reflux temperature of the solvent and may require the presence of a base such as 4- dimethylaminopyπdine, tπethylamine, pyπdine or di-isopropyl ethylamine Treatment of the protected amino compound 3 with an organo-metallic reagent such as a Gπgnard reagent, an alkyl or aryl-zinc reagent, an alkyl or aryl lithium reagent in an inert solvent (tetrahydrofuran. diethylether) under an inert atmosphere (nitrogen or argon) at a suitable temperature from 0°C up to reflux temperature of the solvent will then provide the tertiary alcohol 4 Compound 4 may then be subjected to basic conditions to effect ring closure to give the cyclocarbamate derivative 5 Suitable conditions would involve treatment of 4 with a base such as potassium hydroxide in a solvent such as ethanol or potassium t-butoxide in a solvent such as tetrahydrofuran The reaction can be earned out in an inert atmosphere (nitrogen or argon) from 0°C up to the reflux temperature of the solvent cheme 2 Alternatively the carbamate protecting group present m 4 may be removed under conditions appropriate for its removal to afford 6 (Scheme 2) Subsequent ring closure of 6 with a reagent such as phosgene, carbonyldiimidazole or dimethyl carbonate in an appropriate solvent (tetrahydrofuran, dichloromethane, benzene, etc ) also will provide access to 5 4 7 Scheme 3 Alternatively, compound 4 may be dehydrated to afford the isopropene derivative 7 (Scheme 3) Suitable conditions for the dehydration would be the use of a reagent such as acetic anhydride, methanesulfonyl chloride, p-toluenesulfonyl chloride or tπfluoromethane sulfonyl chloπde or anhydride, in a solvent such as pyπdine, tetrahydrofuran, dichloromethane or benzene The reaction can be earned out under an inert atmosphere (mtrogen or argon) from 0°C up to the reflux temperature of the solvent and may require the presence of a base such as 4-dιmethylammopyndιne, tπethylamine, pyπdine or di-isopropyl ethylamine Exposure of 7 to acidic conditions would then afford ring closure to give 5 Suitable conditions would be the use of an acid such as p-toluenesulfonic acid, methanesulfonic acid or camphorsulfonic acid in a solvent such as dichloromethane, benzene, toluene or tetrahydrofuran The reaction can be carried out under an inert atmosphere (nitrogen or argon) from 0°C up to the reflux temperature of the solvent 11 5 Scheme 4 An alternative route to 5 is shown in Scheme 4 Treatment of the previously descnbed compound 8 (M Sugiyama, T Sakamoto, K. Tabata, K. Endo, K Ito, M Kobayashi, H Fukiumi, Chem Pharm BuU , 37(8) 2091 (1989)) with an organo- metalhc reagent such as a Gπgnard reagent, an alkyl or aryl zinc reagent, an alkyl or aryl lithium reagent in an inert solvent (tetrahydrofuran, diethylether) under an inert atmosphere (mtrogen or argon) at a suitable temperature from 0° C up to reflux temperature of the solvent will then provide the tertiary alcohol 9 Compound 9 may then be subjected to basic conditions to effect πng closure to give the cyclocarbamate deπvative 10 Suitable conditions would involve treatment of 10 with a base such as potassium hydroxide in a solvent such as ethanol or potassium t-butoxide in a solvent such as tetrahydrofuran The reaction can be carried out in an inert atmosphere (nitrogen or argon) from 0° C up to the reflux temperature of the solvent Compound 10 may then be converted to the brominated derivative 11 Suitable conditions would be treatment with bromine or N-bromosuccinimide in a solvent such as dichloromethane, tetrahydrofuran or acetic acid The reaction can be earned out in an inert atmosphere (nitrogen or argon) from 0° C up to the reflux temperature of the solvent in the presence of an additive such as silica gel Subsequent reaction of 11 with an aryl or heteroaryl boronic acid, boronic acid anhydride or tnalkyl stannane then provides access to the desired biaryl compound 5 The reaction can be carried out in a solvent such as acetone, ethanol, benzene, toluene or tetrahydrofuran, under an inert atmosphere (nitrogen or argon) from 0° C up to the reflux temperature of the solvent, in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium (0) or palladium acetate and may require an additive such as sodium carbonate, cesium fluoride or potassium phosphate Scheme 5 Alternatively, 10 (Scheme 5) may be treated at low temperature with a reagent such as an alkyl lithium or lithium amide in an inert solvent such as tetrahydrofuran, and then converted to a boronic acid 12 (M= B(OH) 2 ) under the action of tπmethyl or tπisopropyl borate, or into a stannane via reaction with tπmethyltin chloπde or bιs(tπmethyltιn) Subsequent reaction of 12 with an aryl or heteroaryl bromide or iodide in the presence of a palladium catalyst such as tetrakιs(tπphenylphosphιne) palladium (0) or palladium acetate and may require an additive such as sodium carbonate, cesium fluonde or potassium phosphate, would then effect conversion into the desired thiophene cyclocarbamate 5 B Methods for synthesizing the thiophene cyclocarbamate compounds depicted in Scheme 6 are described below -< Me 17 18 Scheme 6 The amino thiophene compounds 15 (Scheme 6) are prepared according to a literature procedure (Comprehensive Heterocyclic Chemistry II A Review of the Literature 1982-1995 A R Katnsky et al , Vol 2, page 639) which involves treating a suitably substituted aromatic methyl ketone 13 with phosphorus oxychloπde in N,N- dimethyl for amide to afford the chloro cyano olefin deπvative 14. Allowing 14 to react with methyl mercaptoacetate in methanol containing sodium methoxide affords the key aminothiophene carboxylate starting mateπal Reaction of the 2-amιno group with a suitable chloroformate or carbonate affords the protected amine 16 This can be accomphshed by allowing 15 to react with a chloroformate or carbonate derivative such as methyl chloroformate, ethyl chloroformate. allyl chloroformate. 2- (tπmethylsιlyl)ethyl chloroformate or di-tert-butyldicarbonate in a solvent such as benzene, toluene, xylene, dichloromethane, tetrahydrofuran or pyπdine The reaction can be carried out under an inert atmosphere (nitrogen or argon) from 0° C up to the reflux temperature of the solvent and may require the presence of a base such as 4- dimethylaminopyπdme, tπethylamine, pyπdine or di-isopropyl ethylamine Treatment of the protected amino compound 16 with an organo-metallic reagent such as a Gπgnard reagent, an alkyl or aryl-zinc reagent, an alkyl or aryl lithium reagent in an inert solvent (tetrahydrofuran. diethylether) under an inert atmosphere (nitrogen or argon) at a suitable temperature from 0° C up to reflux temperature of the solvent will then provide the tertiary alcohol 17 Compound 17 may then be subjected to basic conditions to effect ring closure to give the cyclocarbamate derivative 18 Suitable conditions would involve treatment of 4 with a base such as potassium hydroxide in a solvent such as ethanol or potassium t-butoxide in tetrahydrofuran The reaction can be carried out in an inert atmosphere (nitrogen or argon) from 0° C up to the reflux temperature of the solvent Scheme 7 Alternatively the carbamate protecting group present in 17 may be removed under conditions appropriate for its removal to afford 19 (Scheme 7) Subsequent ring closure of 19 with a reagent such as phosgene, carbonyldiimidazole or dimethyl carbonate in an appropriate solvent (tetrahydrofuran, dichloromethane. benzene, etc ) also will provide access to 18 Scheme 8 Alternatively, compound 17 may be dehydrated to afford the isopropene derivative 20 (Scheme 8) Suitable conditions for the dehydration would be the use of a reagent such as acetic anhydride, methanesulfonyl chloride, p-toluenesulfonyl chloride or tπfluoromethane sulfonyl chloride or anhydnde, in a solvent such as pyndine, tetrahydrofuran, dichloromethane or benzene The reaction can be carried out under an inert atmosphere (nitrogen or argon) from 0°C up to the reflux temperature of the solvent and may require the presence of a base such as 4-dιmethylamιnopyπdιne, tπethylamine, pyndine or di-isopropyl ethylamine Exposure of 20 to acidic conditions would then afford ring closure to give 18 Suitable conditions would be the use of an acid such as p-toluenesulfomc acid, methanesulfonic acid or camphorsulfonic acid in a solvent such as dichloromethane, benzene, toluene or tetrahydrofuran The reaction can be carried out under an inert atmosphere (nitrogen or argon) from 0°C up to the reflux temperature of the solvent 24 18 Scheme 9 An alternative route to 18 is shown in Scheme 9 Treatment of the previously descnbed compound 21, as taught by H Fukiumi, M Sugiyama, T Sakamoto, Chem Pharm Bull , 37(5) 1197 (1989), with an organo-metalhc reagent such as a Gngnard reagent, an alkyl or aryl zinc reagent, an alkyl or aryl lithium reagent in an inert solvent (tetrahydrofuran, diethylether) under an inert atmosphere (nitrogen or argon) at a suitable temperature from 0° C up to reflux temperature of the solvent will then provide the tertiary alcohol 22 Compound 22 may then be subjected to basic conditions to effect πng closure to give the cyclocarbamate derivative 23 Suitable conditions would involve treatment of 22 with a base such as potassium hydroxide m a solvent such as ethanol or potassium t-butoxide in tetrahydrofuran The reaction can be carried out in an inert atmosphere (nitrogen or argon) from 0° C up to the reflux temperature of the solvent Compound 23 may then be converted to the brominated derivative 24 Suitable conditions would be treatment with bromine or N- bromosuccinimide in a solvent such as dichloromethane, tetrahydrofuran or acetic acid The reaction can be carried out in an inert atmosphere (nitrogen or argon) from 0° C up to the reflux temperature of the solvent in the presence of an additive such as silica gel Subsequent reaction of 24 with an aryl or heteroaryl boronic acid boronic acid anhydride or tnalkyl stannane then provides access to the desired biaryl compound 18 The reaction can be earned out in a solvent such as acetone, ethanol, benzene, toluene or tetrahydrofuran, under an inert atmosphere (nitrogen or argon) from 0° C up to the reflux temperature of the solvent, in the presence of a palladium catalyst such as tetrakιs(tnphenylphosphιne)palladιum (0) or palladium acetate and may require an additive such as sodium carbonate, cesium fluoride or potassium phosphate 23 25 Scheme 10 Alternatively, 23 (Scheme 10) may be treated at low temperature with a reagent such as an alkyl lithium or lithium amide in an inert solvent such as tetrahydrofuran, and then converted to a boronic acid 25 (M= B(OH) 2 ) under the action of tπmethyl or tπisopropyl borate, or into a stannane via reaction with tπmethyltin chlonde or bιs(tπmethyltrn) Subsequent reaction of 25 with an aryl or heteroaryl bromide or iodide in the presence of a palladium catalyst such as tetrakιs(tπphenylphosphιne) palladium (0) or palladium acetate and may require an additive such as sodium carbonate, cesium fluoride or potassium phosphate, would then effect conversion into the desired thiophene cyclocarbamate 18 C. Method for synthesizing the thiophene thiocyclocarbamate compounds 26 and 27 depicted in Scheme 11 are described below 26 18 27 Scheme 11 Thiophene thiocyclocarbamates 26 and 27 may be obtained directly by treating 5 and 18 respectively with phosphorus pentasulfide in refluxing pyπdine Alternatively 5 and 18 may be treated with Lawesson's reagent ([2,4-bιs(4-methoxyphenyl)-l,3-dιthιa-2,4- dιphosphetane-2,4-dιsulfide]) in refluxing pyπdine to afford 26 and 27, respectively Process for making thiazole cyclocarbamate derivatives. Methods for preparing the thiazole cyclocarbamate compounds are described below 28 29 30 30 31 Scheme 12 Thus the thiazole 28 was prepared according to a literature procedure, schemel2 by B Golankiewicz and P Januszczyk, Tetrahedron, 41 5989 (1985) Reaction of the amine 28 with a suitable chloroformate or carbonate then gives the protected amine 29 This may be accomphshed by reacting compound 28 with a chloroformate or carbonate deπvative such as methylchloroformate, ethylchloroformate, allylchloroformate, 2-(tπmethylsιlyl)ethylchloroformate or di-tert- butyldicarbonate in a solvent such as dichloromethane, THF, benzene, xylene or pyndine The reaction can be carried out under an inert atmosphere (nitrogen or argon) from 0 °C up to the reflux temperature of the solvent and may require the presence of a base such as 4-dιmethylamιnopyπdme, tπethylamine, pyπdine or di- lsopropyl ethylamine Exposure of compound 29 to an organo-metalhc reagent such as a Gngnard reagent, an alkyl or aryl-zinc reagent, an alkyl or aryl lithium reagent in an inert solvent (THF, diethyl ether) under an inert atmosphere (nitrogen or argon) at a suitable temperature from 0 °C up to the reflux temperature of the solvent will then provide the alcohol 30 Compound 30 may then be exposed to basic conditions to effect ring closure to give the cyclocarbamate derivative 31 Suitable conditions would involve treatment of compound 30 with a base such as potassium hydroxide in a solvent such as ethanol. The reaction can be earned out under an inert atmosphere (nitrogen or argon) from 0 °C up to the reflux temperature of the solvent 30 32 3 3 1 1 Scheme 13 Alternatively the carbamate protecting group present in compound 30 may be removed under conditions appropriate for its removal to afford compound 32 as taught by T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, second ed., Wiley-Interscience (1991). Subsequent ring closure of compound 32 with a reagent such as phosgene, carbonyl diimidazole or dimethyl carbonate in an appropriate solvent (THF, dichloromethane, benzene, etc) will also provide access to compound 31. 30 33 31 Scheme 14 Alternatively, if compound 30 is a tertiary alcohol then it may be dehydrated to afford the isopropene derivative 33. scheme 3. Suitable conditions for the dehydration would the use of a reagent such as acetic anhydnde, methanesulfonyl chloride, p- toluenesulfonyl chloπde or tπfluoromethane sulfonyl chloπde or anhydnde, in a solvent such as pyπdine, THF, dichloromethane or benzene The reaction can be carried out under an inert atmosphere (nitrogen or argon) from 0 °C up to the reflux temperature of the solvent and may require the presence of a base such as 4- dimethylaminopyπdine, triethylamine, pyndine or di-isopropyl ethylamine Exposure of compound 33 to acidic conditions would then afford ring closure to give compound 31 Suitable conditions would be the use of an acid such as p-toluenesulfomc acid, methanesulfomc acid or camphorsulfonic acid in a solvent such as dichloromethane, benzene, toluene or THF and the reaction can be earned out under an inert atmosphere (nitrogen or argon) from 0 °C up to the reflux temperature of the solvent Scheme 15 Compound 31 may then be converted into the bromide 34, scheme 15 Suitable conditions would be exposure to bromine or N-bromosuccinimide in a solvent such as dichloromethane, THF or acetic acid, the reaction can be earned out under an inert atmosphere (nitrogen or argon) from 0 °C up to the reflux temperature of the solvent in the presence of an additive such as silica gel Subsequent reaction of compound 34 with an aryl or heteroaryl boronic acid, boronic acid anhydride or tnalkyl stannane then provides access to the desired biaryl compound 35 The reaction can be carried out in a solvent such as acetone, ethanol, benzene, toluene or THF, under an inert atmosphere (nitrogen or argon) from 0 °C up to the reflux temperature of the solvent, in the presence of a palladium catalyst such as tetrakιs(tπphenylphosphιne) palladium (0) or palladium acetate and may require an additive such as sodium carbonate, cesium fluoride or potassium phosphate 31 36 35 Scheme 16 Alternatively compound 31 may be treated at low temperature with a reagent such as an alkyl lithium or lithium amide in an inert solvent such as THF, and then converted into a boronic acid (M = B(OH) 2 ) 36 under the action of tπmethyl or tπisopropyl borate, or into a stannane under the action of tπmethyltin chloπde or bιs(tπmethyltιn), Scheme 16 Subsequent reaction with an aryl or heteroaryl bromide or iodide in the presence of a palladium catalyst such as tetrakιs(tπphenylphosphιne) palladium (0) or palladium acetate and may require an additive such as sodium carbonate, cesium fluoride or potassium phosphate would then effect conversion into the desired compound 35 AMIDE DERIVATIVES Process for making amide thiophene derivatives. A method for preparing thiophene derivatives is described below, scheme 17 CO.Me „C0 2 Me CO.H R 4 - R 4 - S' NH 2 S' NHCO,R NHC0 2 R 3 7 3 8 3 9 4 0 4 1 2 43 ΛΛ Scheme 17 Thus the amine 37 is converted into a carbamate, such as a tert-butyl carbamate as descnbed in scheme 1 for the preparation of compound 2 Hydrolysis of the ester 38 under basic conditions, for example lithium or sodium hydroxide in THF or methanol at room temperature then gives the acid 39 Conversion of the acid 39 into the acid chloride 40 is accomplished under standard conditions, thionyl chloride or oxalyl chloride either neat or in the presence of a solvent such as dichloromethane and an additive such as a catalytic amount of N,N-dιmethylformamιde Compound 40 is then reacted with diazomethane or tπmethylsilyldiazomethane in an inert solvent such as THF or dichloromethane. and the product diazoketone 41 is then rearranged in the presence of silver (I) oxide to afford the acid 42 Treatment of compound 42 under conditions that specifically remove the protecting carbamate functionality, for example acidic conditions, will then affect cychzation to give compound 43 Reaction of compound 43 with an alkylating agent such as an alkyl iodide, bromide, tosvlate or mesylate, or a bis-alkyl iodide, bromide, tosylate or mesylate, under basic conditions, for example butyl lithium in the presence of N.N,N,N-tetramethylene diamine in a solvent such as THF under an inert atmosphere (nitrogen or argon) at a temperature between -78 °C and the boiling point of the solvent, will then afford the alkylated derivative 44 Process for making thiazole derivatives. A method for preparing thiazole derivatives is described below, scheme 18 29 45 46 47 48 49 50 51 52 53 Scheme 18 Hydrolysis of the ester 29 under basic conditions, for example lithium or sodium hydroxide in THF or methanol at room temperature then gives the acid 45 Conversion of the acid 45 into the acid chloride 46 is accomplished under standard conditions, for example thionyl chloπde or oxalyl chloride either neat or in the presence of a solvent such as dichloromethane and an additive such as a catalytic amount of N,N-dιmethylformamιde Compound 46 is then reacted with diazomethane or tπmethylsilyldiazomethane in an inert solvent such as THF or dichloromethane, and the product diazoketone 47 is then reaπanged in the presence of silver (I) oxide to afford the acid 48 Treatment of compound 48 under conditions that specifically remove the protectmg carbamate functionality, for example acidic conditions, will then affect cyclization to give the heterocycle 49 Reaction of compound 49 with an alkylating agent such as an alkyl iodide, bromide, tosylate or mesylate, or a bis-alkyl iodide, bromide, tosylate or mesylate, under basic conditions, for example butyl hthium in the presence of N,N,N,N-tetramethylene diamine in a solvent such as THF under an inert atmosphere (mtrogen or argon) at a temperature between -78 °C and the boiling point of the solvent, will then afford the alkylated heterocycle 50 Compound 50 may then be converted into the bromide 51 Suitable conditions would be exposure to bromine or N-bromosuccinimide in a solvent such as dichloromethane, THF or acetic acid, the reaction can be earned out under an inert atmosphere (nitrogen or argon) from 0 °C up to the reflux temperature of the solvent in the presence of an additive such as sihca gel Subsequent reaction of compound 51 with an aryl or heteroaryl boronic acid, boromc acid anhydride or tnalkyl stannane then provides access to the desired biaryl compound 52 The reaction can be carried out in a solvent such as acetone, ethanol, benzene, toluene or THF, under an inert atmosphere (nitrogen or argon) from 0 °C up to the reflux temperature of the solvent, in the presence of a palladium catalyst such as tetrakιs(tπphenylphosphιne) palladium (0) or palladium acetate and may require an additive such as sodium carbonate, cesium fluonde or potassium phosphate The thione deπvative. compound 53, may be obtained drrecth by treating 52 with phosphorus pentasulfide in refluxing pyndine Alternatively 52 may be treated with Lawesson ' s reagent in refluxing pyndine to afford 53. The anti-progestin compounds of the formulations of the present invention can be used in the form of salts derived from pharmaceutically or physiological!} acceptable acids or bases These salts include, but are not limited to, the following salts with inorganic acids such as hydrochloric acid, sulfunc acid, nitπc acid, phosphoπc acid and, as the case may be, such organic acids as acetic acid, oxalic acid, succinic acid, and maleic acid Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium in the form of esters, carbamates and other conventional "pro-drug" forms, which, when administered in such form, convert to the active moiety in vivo These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary amenoπhea, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, carcinomas and adeno carcinomas of the endometπum, ovary, breast, colon, prostate, or minimization of side effects or cyclic menstrual bleeding Additional uses of the mvention include stimulation of food intake When the combmed compounds are employed for the utilities descπbed above, they may be combined with one or more pharmaceutically acceptable earners or excipients, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0 05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol. and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0 05 to 5% suspending agent in an lsotoruc medium Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as com. peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired Adjuvents customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, colonng agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard- filled or hquid-filled capsules Oral administration of the compounds is preferred These active compounds may also be administered parenterally or intrapentoneally Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions In all cases, the form must be sterile and must be fluid to the extent that easy syringe ability exits It must be stable under conditions of manufacture and storage and must be preserved against the contammating action of microorganisms such as bactenal and fungi The carrier can be a solvent or dispersion medium containing, for example, water, ethanol (e g , glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil The following non-limiting examples are illustrative of exemplary compound 5. EXAMPLE 1 6-(3-chlorophenyl)-l,4-dihydro-4.,4-dimethyl-2H-thieno[2,3-dl[l.,31oxazine-2-one 2-(3-Chlorobenzyl)acetaldehyde To a 25°C solution of 3-chlorostyrene in anhydrous CH 2 C1 2 ( 10 Og, 72 15 mmol) was added a well-stirred solution of Pb(OAc) ( 35 2g, 79 4mmol) in tπfluoroacetic acid (150mL), dropwise Reaction was completed within 30 minutes of the addition and after being stiπed for a further 30 minutes, the mixture was poured into water, extracted with ether (3X), the combined organic layers were washed with saturated NaHC0 3 solution, water, dried ( MgS0 4 ), and concentrated to a volume of about 15 mL and immediately used for the following reaction descnbed below 2-Amιno-5-(3-chloro-phenyl)-thιophene-3-carboxyhc acid methyl ester To the crude aldehyde, prepared above, in methanol was added a mixture of sulfur (2 55g, 79 44mmol), methylcyanoacetate (7 88 g, 79 44 mmol), morphohne (6 92g, 79 44) and the resulting reaction mixture was refluxed for 16 hours The unreacted sulfur was filtered off and the filtrates were evaporated leaving behind a black residue This residue was extracted with ether, washed with H 2 0 Crystallized from ether/hexane (1 5) to obtain white crystals (3 85g, 14 3mmol, 50%), mp 85-87°, *H NMR (DMSO-d 6 ) δ 3 75 (s, 3H), 7 18-7 27 (m, IH), 7 31-7 42 (m, 3H), 7 53 (s. IH), 7 62 (s, IH), MS(+APCI) m/z268(M+H), Anal Calc For C 12 Hι 0 ClNO 2 S C, 53 83, H, 3 76, N, 5 23 Found C, 53 57, H, 3 37, N, 5 00 2-Allyloxycarbonylain_no-5-(3-chloro-phenyl)-thiophene-3-carboxyhc acid methyl ester To a solution of 2-amιno-5-(3-chloro-phenyl)-thιophene-3-carboxylιc acid methyl ester (2g, 7 5 mmol) in anhydrous 1.2-dιchloroethane (50 mL) was added at room temperature under nitrogen allyl chloroformate (1 6 mL. 15 1 mmol) The reaction mixture was heated at reflux under nitrogen for 18 hours, cooled to room temperature, and treated with a saturated aqueous sodium bicarbonate solution (100 mL) The organic layer was separated and aqueous layer was extracted with methylene chloride (3x20 mL) The combined organic layers were washed (brine) and dπed (MgS0 4 ) After removal of the solvent, the residue was purified by a flash silica gel column (hexane ethyl acetate/7 1) to give the subtitled compound as an off-white solid (2 14g, 81%) Η-NMR (OMSO-d 6 ) δ 10 2 (s, IH), 7 73 (t, IH. J= 1 7 Hz). 7 66 (s, IH), 7 57 (dt, IH. J = 7 7, 1 7 Hz), 7 41 (t, IH, J= 7 7 Hz), 7 34 (dt, IH, J = 6 8, 1 6 Hz), 6 01 (m, IH), 5 41 (dd, 1H, J= 7 3, 1 6 Hz), 5 29 (dd, 1H, J = 10 5, 1 3 Hz), 4 74 (d, 2H, J= 5 5 Hz), 3 84 (s, 3H) Anal Calc For Cι 6 Hι 4 ClN0 4 S C, 54 63, H, 4 01, N, 3 98 Found C, 54 56, H, 3 92, N, 3 89 To a solution of 2-allenoxycarbonylamιno-5-(3-chloro-phenyl)-thιophene-3- carboxyhc acid methyl ester (0 lg, 0 28 mmol) in anhydrous THF was added a solution of methylmagnesium bromide (3 0 M in diethyl ether, 1 5 mL, 4 5 mmol) at room temperature under mtrogen After stirring at room temperature under nitrogen for 20 minutes, the reaction mixture was treated with brine (10 mL) followed by addition of an aqueous IN HCl solution (5 mL) Ethyl acetate (20 mL) was added and orgamc layer was separated, washed with brine (5 mL) and dried over MgS0 4 After removal of solvent, the residue was purified by a flash column (silica gel, hexane ethyl acetate/5 1) to give carbinol which was used in next step without further purification and characterization A mixture of above crude carbinol, potassium hydroxide (excess) in ethanol was stirred at room temperature under nitrogen overnight The reaction solution was then acidified by an addition of a cold aqueous IN HCl solution Ethyl acetate (20 mL) was added and organic layer was separated, washed with brine (5 mL) and dried (MgS0 ) After removal of the solvent, the residue was purified b a silica gel column (hexane ethyl acetate/2 1) to give the title compound as an off-white solid (16 mg. 19% for two steps) mp 149-150 °C, ! H-NMR (DMSO-J d ) δ 10 69 (s, IH), 7 64 (t, IH, J = 1 8 Hz), 7 49 (s, IH). 7 47 (dt, IH, J= 7 7, 1 4 Hz). 7 39 (t. IH, J= 1 8 Hz) 7 29 (dt. IH, J = 7 8, 1 3 Hz), 1 61 (s, 6H) MS (El) m/z 293/295 (M") Anal Calc For C 14 H 12 C1N0 2 S C, 57 24, H, 4 12, N, 4 77 Found C, 57 27, H, 4 25, N, 4 66 EXAMPLE 2 6-(3-chlrophenyl)-l,4-dihydro-4,4-dimethyl-2H-thieno[3,2-d][l,3]oxazine-2-one 3-Chloro-3-(3-chlor-phenyl)-acrylonιtnle A solution of P0C1 3 was slowly added to anhydrous DMF over a peπod of 20 minutes and the temperature was maintained around 30°C 3'-Chloroacetophenone solution in anhydrous DMF was added to the above solution and the reaction temperature was allowed to πse to around 50°C Hydroxylamine HCl was added to the reaction solution, portionwise, over 1 hour A volume of 500 mL of water was added to form precipitate, stirred for 1 hour and the precipitate was collected on a Buchner funnel, washed with H 2 0, and dned to afford a yellow crystalline compound, mp 60-62°C *H NMR (DMSO-d 6 ) δ 1 60 (s, 6H), 7 30 (d, IH, J= 8 41Hz). 7 41 (d, IH, J= 8 41Hz), 10 47 (s, IH), MS(+APCI)m/z 213(M+H), Anal Calc For C 9 H 9 C1N 2 0 2 C, 50 84, H, 4 27, N, 13 17 Found C, 50 99, H, 4 28, N, 12 98 3-Amιno-5-(3-chloro-phenyl ' )-thιophene-2-carboxyhc acid methyl ester Sodium pellets were slowly added to methanol solution to formNaOMe in situ, then methyl thioglycolate was added over a peπod of 20 minutes to the methanol solution A solution of 3-Chloro-3-(3-chloro-phenyl)-acrylonιtπle in methanol was added slowly and was brought to reflux for 1 hour The reaction mixture was cooled to room temperature and methanol was concentrated to 100 mL and 200 mL of water was added, stirred for 30 mm and the yellow precipitate was collected and washed with water several times to yield a yellow crystalline compound, mp 92-95°C X H NMR (DMSO-d 6 ) δ 1 60 (s, 6H), 7 30 (d. 1H, J= 8 41Hz), 7 41 (d, lH, J = 8 41Hz), 10 47 (s, IH), MS (+APCI) m/z 213(M+H), Anal Calc For C 9 H 9 C1N 2 0 2 C. 50 84. H, 4 27, N, 13 17 Found C, 50 99, H, 4 28, N, 12 98 3-Allyloxycarbonylamιno-5-(3-chloro-phenyl)-thιophene-2-carboxyhc acid methyl ester To a solution of 3-Amιno-5-(3-chloro-phenyl)-thιophene-2-carboxyhc acid methyl ester (15g, 56 Ommol) in toluene (200mL) was added a solution of allyl chloroformate (8 1 Og, 67 2mmol) in toluene (5 OmL) and the resulting reaction solution was heated under reflux for 3 hours Toluene was stπpped down and the crystals were collected and washed with ether/hexane to afford a yellow crystalline compound, mp 101-103°C *H NMR (DMSO-d 6 ) δ 3 85 (s, 3H), 4 68-4 71 (d, 2H, J = 5 46Hz), 5 26-5 30 (dd, IH, J= X 35, 9 84Hz), 5 36-5 42 (dd, IH, J= X 57, 15 68Hz), 5 96 (m, 2H), 7 50-7 52 (m, 2H), 7 67-7 71 (m, IH), 7 79 (s, IH), 8 10 (s, IH), MS(+APCI) m/z 352(M+H), Anal Calc For C 16 H 14 C1N0 4 S C, 54 63, H, 4 01, N, 3 97 Found C, 54 05, H, 4 17, N, 3 84 [5-(3-Chloro-phenyl)-2-(l-hydroxy-l-methyl-ethyl)-thιophen-3-yl]-carbamιc acid allyl ester To a solution of 3-Allyloxycarbonylamιno-5-(3-chloro-phenyl)-thιophene-2- carboxy c acid methyl ester (5 3g, 15 lmmol) in anhydrous THF (30mL) at room temperature was added a solution of 3 0M MeMgl in ether (20 lmL, 60 24mmol) After 30 minutes, the reaction was slowly quenched with H 2 0 (lOmL), treated with saturated NH 4 OH (lOOmL), extracted with ether (200mL), washed with bnne, dried (MgS0 ), concentrated, and chromatographed (hexane/ ether, 1 4) mp 60-61, Η NMR (DMSO-de) δ 1 52 (s, 6H), 4 59-4 61 (d, 2H, J = 5 35Hz), 5 22-5 36 (m, 2H), 5 91-6 04 (m, 2H), 7 33-7 67 (m, 5H), 8 89 (s, IH), MS(EI) m/z 351/353(M+H), Anal Calc For C 17 H 18 C1N0 3 S C, 58 03, H, 5 16, N. 3 98 Found C, 58 17. H, 5 16, N, 3 97 6-(3-Chlorophenyl)-1.4-dιhyrdro-4.4-dιmethyl-2H-thιeno 3.2-diπ.31oxazιn-2-one To a solution of [5-(3-Chloro-phenyl)-2-(l-hydroxy-l-methyl-ethyl)-thιophen- 3-yl]-carbamιc acid allyl ester ( 12g, 34mmol) in anhydrous THF (5 OmL) was added KO'Bu (0 076g, 0 068mmol) and stirred for 15 min, quenched with H 2 0, and m situ crystallization was carried out by adding minimal amount of MeOH to the solution The white crystals were collected on a Buchner funnel, mp 123-125°C : H NMR (DMSO-dβ) δ 1 64 (s. 6H). 7 05 (s, IH), 7 37-7 48 (m, 2H), 7 53-7 56 (s. IH), 7 67- 7 68 (m, IH), 10 41 (s. IH), MS(EI) m/z 293/295(M+H), Anal Calc For C 17 Hι 8 ClN0 3 S C, 57 24. H, 4 12, N, 4 77 Found C, 56 93, H, 3 92, N, 4 97 Example 3 - Pharmacology The progestational activity of the current invention was evaluated in the PRE-luciferase assay in CV-1 cells, described below In-vitro potencies can be in the range 0 01nM-10,000nM In vivo potencies are anticipated to be in the range 1 mg/kg to 30 mg/kg The object of this assay is to determine a compound's progestational or antiprogestational potency based on its effect on PRE-luciferase reporter activity in CV-1 cells co-transfected with human PR and PRE-luciferase plasmids The mateπals methods used in the assay are as follows a Medium The growth medium was as follows DMEM (BioWhittaker) containing 10% (v/v) fetal bovine serum (heat inactivated). 0 1 mM MEM non-essential amino acids, lOOU/ml penicillin. lOOmg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL) The experimental medium was as follows DMEM (BioWhittaker), phenol red-free, containing 10% (v/v) charcoal-stripped fetal bovine serum (heat-inactivated). 0 1 mM MEM non-essential amino acids. lOOU/ml penicillin. lOOmg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL) b Cell culture, transfection. treatment, and luciferase assay Stock CV-1 cells are maintained in growth medium Co-transfection is done using 1 2x10 7 cells, 5 mg pLEM plasmid with hPR-B inserted at Sphl and BamHl sites. 10 mg pGL3 plasmid with two PREs upstream of the luciferase sequence, and 50 mg sonicated calf thymus DNA as carrier DNA in 250 ml Electroporation is carried out at 260 V and 1,000 mF in a Biorad Gene Pulser II After electroporation. cells are resuspended in growth medium and plated in 96-well plate at 40,000 cells/well in 200 μl Following overnight incubation, the medium is changed to experimental medium Cells are then treated with reference or test compounds m expenmental medium Compounds are tested for antiprogestational activity in the presence of 3 nM progesterone Twenty-four hr after treatment, the medium is discarded, cells are washed three times with D-PBS (GIBCO, BRL) Fifty μl of cell lysis buffer (Promega, Madison, WI) is added to each well and the plates are shaken for 15 min in a Titer Plate Shaker (Lab Line Instrument, Inc ) Luciferase activity is measured using luciferase reagents from Promega c Analysis of Results Each treatment consists of at least 4 replicates Log transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes Huber weighting is used to downweight the effects of outhers EC50 or IC 50 values are calculated from the retransformed values JMP software (SAS Institute, Inc ) is used for both one-way analysis of variance and non-hnear response analyses d Reference Compounds Progesterone and tnmegestone are reference progestins and RU486 is the reference antiprogestin All reference compounds are run in full dose-response curves and the EC5 0 or IC 50 values are calculated Table 1. Estimated EC50, standard error (SE), and 95% confidence intervals (CI) for reference progestins from three individual studies EC50 95% CI Compound Exp nM SE lower upper Progesterone 1 0616 0026 0509 0746 2 0402 0019 0323 0501 3 0486 0028 0371 0637 Tnmegestone 1 00075 00002 00066 00085 2 00081 00003 00070 00094 3 00067 00003 00055 00082 Table 2. Estimated IC 50 , standard error (SE), and 95% confident interval (CI) for the antiprogestin, RU486 from three individual studies IC 50 95% CI Compound Exp (nM) SE lower upper RU486 1 0028 0002 0019 0042 2 0037 0002 0029 0048 3 0019 0001 0013 0027 Progestational activity Compounds that increase PRE-luciferase activity significantly (p<0 05) compared to vehicle control are considered active Antiprogestational activity Compounds that decrease 3 nM progesterone induced PRE-luciferase activity significant-} (p<0 05) EC50 Concentration of a compound that gives half-maximal increase PRE- luciferase activity (default-nM) with SE IC 50 Concentration of a compound that gives half-maximal decrease in 3 nM progesterone induced PRE-luciferase activity (default-nM) with SE All publications cited in this specification are incorporated herein by reference herein While the invention has been described with reference to a particularly prefeπed embodiment, it will be appreciated that modifications can be made without departing from the spirit of the invention Such modifications are intended to fall within the scope of the appended claims

Claims: What is Claimed: 1 A method of contraception which compnses administering to a female of child bearing age for 28 consecutive days a) a first phase of from 14 to 24 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 100 μg levonorgestrel, b) a second phase of from 1 to 11 daily dosage units, at a daily dosage of from about 2 to 50 mg, of an antiprogestin compound of Formula 1 wherein A and B are independent substituents selected from S, CH or N, Provided that when A is S, B is CH or N, provided that when B is S, A is CH or N. and A and B cannot both be CH. and when A and B both equal N. one N may be optionalh substituted with an C to C 6 alkyl group, Ri and R 2 are independent substituents selected from the group of H. Ci to C alkyl, substituted Ci to Cβ alkyl, C 2 to C 6 alkenyl, substituted C 2 to C 6 alkenyl. C 2 to C 6 alkynyl, substituted C to C 6 alkynyl. C 3 to C 8 cycloalkyl, substituted C^ to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocyclic. COR A . or NR B COR A , or R 1 and R 2 are fused to form a) an optionally substituted 3 to 8 membered spirocyclic alkyl ring, or b) an optionally substituted 3 to 8 membered spirocyclic alkenyl πng. or c) an optionally substituted 3 to 8 membered spirocyclic ring containing one to three heteroatoms selected from the group of O, S and N, R A is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl. Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyk R B is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl; R 3 is H, OH, NH 2 , Ci to C 6 alkyl, substituted d to C 6 alkyl, C 3 to C 6 alkenyl, substituted Ci to Cβ alkenyl, alkynyl, or substituted alkynyl, or COR c ; R c is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted C\ to C 3 aminoalkyl; R 4 is a tπsubstituted benzene ring containing the substituents X, Y and Z as shown below. X is selected from halogen, CN, C_ to Ci alkyl. substituted Ci to C 3 alkyl. Ci to C 3 alkoxy. substituted Ci to C 3 alkoxy. Ci to C 3 thioalkyl. substituted Ci to C , thioalkyl. Ci to C 3 aminoalkyl, substituted Ci to C 3 aminoalkyl. N0 2 . Ci to C 3 perfluoroalkyl. 5 or 6 membered heterocyclic ring containing 1 to 3 heteroatoms. COR D . OCOR D . or NR L COR D . R D is H, Ci to alkyl. substituted Ci to alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, d to C 3 aminoalkyl, or substituted d to C 3 aminoalkyl, R E is H. Ci to C 3 alkyl, or substituted Ci to C 3 alkyl, Y and Z are independently selected from H, halogen, CN, N0 2 . Ci to Ci alkoxy, Ci to C 3 alkyl. or d to C 3 thioalkyl, or R 4 is a five or six membered ring with 1, 2, or 3 heteroatoms selected from O, S, SO, S0 2 or NR 5 , the five or six membered rings being optionally substituted by one or two independent substituents selected from H, halogen, CN, N0 2 and Ci to C 3 alkyl, Ci to C 3 alkoxy, d to C 3 aminoalkyl, COR F , or NR G COR F , R F is H, d to C 3 alkyl, substituted d to C 3 alkyl, aryl, substituted aryl. d to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted d to C 3 aminoalkyl, R G is H, d to C 3 alkyl, or substituted to d alkyl, R 5 is H, or Ci to d alkvl. W is O or a chemical bond. or a pharmaceutically acceptable salt thereof, and c) optionally, a third phase of daily dosage units of an orally and pharmaceutically acceptable placebo for the remaining days of the 28 consecutive da\s m which no antiprogestin. progestin or estrogen is administered, wherein the total daily dosage units of the first, second and third phases equals 28 2 A method of Claim 1 wherein the progestational agent is levonorgestrel and the anti-progestin compound is selected from those of Formula 1 of Claim 1 wherein A and B are independent substituents S, CH or N, provided that when A is S, B is CH or N, and when B is S, A is CH or N, and A and B cannot both be CH, and when A and B both equal N, one N may be optionally substituted with an Ci to β alkyl group, R 1 is H, Ci to C 6 alkyl, substituted d to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocychc, COR A , or NR B COR A , R 2 is H, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 2 to C 6 alkenyl, substituted C 2 to Cβ alkenyl, C 2 to Cβ alkynyl, substituted C 2 to Cβ alkynyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc. COR A , or NR B COR A , or R 1 and R 2 are fused to form a) an optionally substituted 3 to 8 membered spirocyclic alkyl ring, or b) an optionally substituted 3 to 8 membered spirocyclic alkenyl πng. or c) an optionally substituted 3 to 8 membered spirocyclic ring containing one to three heteroatoms selected from the group of O, S and N. R A is H, Ci to alkyl, substituted Ci to C 3 alkyl. aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy. Ci to d aminoalkyl. or substituted Ci to C 3 aminoalkyl, R B is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl. R 3 is H, OH, NH 2 , Ci to C 6 alkyl, substituted d to C 6 alkyl, C 3 to C 6 alkenyl. substituted Ci to Cβ alkenyl, alkynyl, or substituted alkynyl, or COR c , R c is H, Ci to C 4 alkyl, substituted Ci to C 4 alkyl, aryl, substituted aryl. Ci to C alkoxy, substituted Ci to C 4 alkoxy, Ci to C 4 aminoalkyl, or substituted Ci to C 4 aminoalkyl. R 4 is a tπsubstituted benzene πng containing the substituents X, Y and Z as shown below X is taken from the group including halogen, CN, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy. d to C 3 thioalkyl, substituted d to C 3 thioalkyl, Ci to C 3 aminoalkyl, substituted d to C 3 aminoalkyl, N0 , Ci to C 3 perfluoroalkyl, 5-membered heterocyclic πng containing 1 to 3 heteroatoms, COR D , OCOR D , or NR E COR D , R D is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalky l. or substituted d to C aminoalkyl, R E is H, d to d alkyl, or substituted d to C 3 alkyl. Y and Z are independent substituents taken from the group including H. halogen, CN. N0 2 . Cj to C 3 alkoxy, d to alkyl. or d to d thioalkyl, or R 4 is a five or six membered ring with 1. 2. or 3 heteroatoms selected from O. S, SO, S0 2 or NR 5 , the five or six membered ring being optionally substituted by one or two independent substituents selected from H, halogen, CN, N0 2 and Ci to C 3 alkyl, or Ci to C 3 alkoxy, R 5 is H or Ci to C alkyl, W is O or a chemical bond or a pharmaceutically acceptable salt thereof 3 A method of Claim 1 wherein the progestational agent is levonorgestrel and the anti-progestin compound is selected from those of Formula 1 of Claim 1 wherein A and B are independent substituents from the group including S, CH or N, provided that when A is S, B is CH or N, and when B is S, A is CH or N, and A and B cannot both be CH, R 1 = R 2 and are selected from the group which includes d to C 3 alkyl. substituted d to C 3 alkyl. or spirocyclic alkyl constructed by fusing R 1 and R 2 to form a 3 to 6 membered spirocyclic ring, R 3 is H, OH, NH 2 , Ci to C 6 alkyl. substituted Ci to C 6 alkyl. or COR c , R c is H, Cj to C 4 alkyl. or d to C 4 alkoxy, R 4 is a disubstituted benzene ring containing the substituents X and Y as shown below X is selected from the group including halogen, CN, d to C 3 alkoxy. Ci to C 3 alkyl, N0 2 , Ci to C 3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or d to C 3 thioalkyl. Y is a substituent on the 4' or 5' position selected from the group of H. halogen, CN, N0 2 , Ci to C 3 alkoxy, d to C 4 alkyl, or d to C 3 thioalkyl, or R 4 is a five membered πng with the structure shown below R 3 is H, or Ci to C 3 alkyl, or Ci to C 4 C0 2 alkyl, X' is selected from halogen, CN. N0 . d to C 3 alkyl or Ci to C alkoxy. Y " is H or Ci to C 4 alkyl, or R 4 is a six membered ring with the structure X 2 is halogen, CN or N0 2 , W is O or a chemical bond, or a pharmaceutically acceptable salt thereof 4 A method of Claim 1 wherein the progestational agent is levonorgestrel and the anti-progestin compound is selected from those of Formula 1 of Claim 1 wherein R 1 = R 2 and are selected from the group which includes Ci to C 3 alkyl. substituted d to C 3 alkyl. or spirocyclic alkyl constructed by fusing R 1 and R 2 to form a 3 to 6 membered spirocychc ring, and A, B, R 3 , R c , R 4 , X, Y, U, R 5 , X', Y\ X 1 , X 2 , R 6 , R 7 , R 8 , R 9 and W are as defined in Claim 3, or a pharmaceutically acceptable salt thereof 5 A method of Claim 1 wherein the progestational agent is levonorgestrel and the anti-progestin compound is selected from those of Formula 1 of Claim 1 wherein R 1 and R 2 are fused to form a 3 to 6 membered spirocychc πng, and A, B, R 3 . R c , R 4 , X. Y. U, R 5 , X', Y\ X 1 , X 2 , R 6 , R 7 , R 8 , R 9 and W are as defined in Claim 3, or a pharmaceutically acceptable salt thereof 6 A method of contraception which comprises administering to a female of child bearing age for 28 consecutive days a) a first phase of from 14 to 24 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 100 μg levonorgestrel, b) a second phase of from 1 to 11 daily dosage units, at a daily dosage of from about 2 to 50 mg, of an antiprogestin compound of the formula wherein Ri and R 2 are independent substituents selected from the group of H, Ci to Cβ alkyl, substituted Ci to C alkyl, C 2 to Cβ alkenyl, substituted C 2 to C alkenyl, C 2 to C 6 alkynyl, substituted C 2 to C 6 alkynyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, COR A , or NR B COR A , or R 1 and R 2 are fused to form a) a 3 to 6 membered spirocyc c alkyl πng, or b) a 3 to 6 membered spirocychc alkenyl ring, R 3 is H, OH, NH 2 , Ci to C 6 alkyl, substituted d to C 6 alkyl, C 3 to C 6 alkenyl. substituted Ci to C 6 alkenyl. alkynyl, or substituted alkynyl, or COR c . R B is H, Ci to C 3 alkyl, or substituted d to C 3 alkyl, R is H, Ci to C 3 alkyl. substituted Ci to C 3 alkyl. aryl, substituted aryl. Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl. or substituted Ci to C 3 aminoalkyl, R 4 is a tπsubstituted benzene nng containing the substituents X, Y and Z as shown below, X is selected from halogen, CN, Ci to alkyl, substituted Ci to alkyl, d to C 3 alkoxy, substituted Ci to C 3 alkoxy. Ci to C thioalkyl substituted Ci to C 3 thioalkyl, Ci to C 3 aminoalkyl, substituted Ci to aminoalkyl, N0 2 , Ci to d perfluoroalkyl, 5 or 6 membered heterocychc ring containing 1 to 3 heteroatoms, COR D , OCOR D , or NR E COR D , R D is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, C t to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl, R E is H, d to C 3 alkyl, or substituted Ci to C 3 alkyl, and Y and Z are independently selected from H, halogen, CN, N0 2 , Ci to C 3 alkoxy, d to C 3 alkyl, or Ci to C 3 thioalkyl, or a pharmaceutically acceptable salt thereof, and c) optionally, a third phase of daily dosage units of an orally and pharmaceutically acceptable placebo for the remaining days of the 28 consecutive days in which no antiprogestin, progestin or estrogen is administered, wherein the total daily dosage units of the first, second and third phases equals 28 7 A method of Claim 1 in which the antiprogestin compound is 6-(3- chlorophenyl)-l,4-dιhydro-4,4-dιmethyl-2H-thιeno[2.3-d][1.3]oxazιne-2-one, or a pharmaceutically acceptable salt thereof 8 The method of Claim 1 wherein the progestational agent is selected from the group of levonorgestrel, norgestrel, desogestrel, 3-ketodesogestrel, norethindrone, gestodene, norethindrone acetate, norgestimate, osaterone, cyproterone acetate, tnmegestone, dienogest, drospirenone, nomegestrol, or (17- deacetyl)norgestιmate 9 A method of Claim 1 which comprises administering to a female of child bearing age consecutively over a 28 day cycle a) a first phase of 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 100 μg levonorgestrel, b) a second phase of 3 daily dosage units of an antiprogestin compound of Claim 1, each daily dosage umt containing an antiprogestin compound at a daily dosage of from about 2 to 50 mg, and c) optionally, 4 daily dosage units of an orally and pharmaceutically acceptable placebo to be admimstered on each day of the 28-day cycle following the first phase and second phase 10 A method of contraception which compπses administering to a female of child bearing age over a peπod of 28 consecutive days a) a first phase of from 18 to 21 daily dosage units of a progestostational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel, and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg, and b) a second phase of from 1 to 7 daily dosage units of an antiprogestin of Claim 1 at a daily dose of from about 2 to 50 mg, and c) optionally, an orally and pharmaceutically acceptable placebo for each remaining day of the 28 consecutive days 11 A method of contraception of Claim 10 which comprises administenng to a female of child bearing age over a period of 28 consecutive days a) a first phase of 21 daily dosage units of a progestostational agent equal in progestational activity to about 35 to about 100 μg levonorgestrel and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg, and b) a second phase of 3 daily dosage units of an antiprogestin of Claim 1 at a daily dose of from about 2 to 50 mg, and c) optionally , a third phase of 4 daily dosage units of an orally and pharmaceutically acceptable placebo 12 A method of contraception which compπses administering to a female of child bearing age over a penod of 28 consecutive days a) a first phase of from 18 to 21 daily dosage units containing a progestational agent at a daily dose equal in progestational activity to from about 35 to about 150 μg levonorgestrel and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg b) a second phase of from 1 to 7 daily dose units, each daily dose umt contaimng an antiprogestin of Claim 1 at a concentration of from 2 to 50 mg and ethinyl estradiol at a concentration of from about 10 to about 35 μg, and c) optionally , a third phase of daily dosage units of an orally and pharmaceutically acceptable placebo, the total of the daily dosage units being 28 13 A method of contraception of Claim 12 administering to a female of child bearing age over a period of 28 consecutive days a) a first phase of 21 daily dosage units, each daily dosage unit containing a progestational agent at a daily dose equal in progestational activity to about 35 to about 100 μg levonorgestrel and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg b) a second phase of 3 daily dose, each daily dose umt containing an antiprogestin of Claim 1 at a concentration of from 2 to 50 mg, and ethmyl estradiol at a concentration of from about 10 to about 35 μg, and c) optionally, a third phase of 4 daily dosage units of an orally and pharmaceutically acceptable placebo 14 A pharmaceutically useful kit adapted for daily oral administration which comprises a) a first phase of from 14 to 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel, b) a second phase of from 1 to 11 daily dosage units of an antiprogestin compound of Claim 1, each daily dosage umt containing an antiprogestm compound at a daily dosage of from about 2 to 50 mg, and c) a third phase of daily dosage units of an orally and pharmaceutically acceptable placebo, wherein the total number of the daily dosage units in the first phase, second phase and third phase equals 28 15 A pharmaceutically useful kit adapted for daily oral administration of Claim 14 which comprises a) a first phase of 21 daily dosage units of a progestational agent equal m progestational activity to about 35 to about 150 μg levonorgestrel. b) a second phase of 3 daily dosage units of an antiprogestin compound of Claim 1, each daily dosage unit containing an antiprogestin compound at a daily dosage of from about 2 to 50 mg, and c) a third phase of 4 daily dosage units of an orally and pharmaceutically acceptable placebo 16 A pharmaceutically useful kit adapted for daily oral administration which comprises a) a first phase of from 18 to 21 daily dosage units of a progestostational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg, and b) a second phase of from 1 to 7 daily dosage units of an antiprogestin of Claim 1 at a daily dose of from about 2 to 50 mg, and c) a third phase of from 0 to 9 daily dosage units of an orally and pharmaceutically acceptable placebo, wherein the total number of the daily dosage units in the first phase, second phase and third phase equals 28 17 A pharmaceutically useful kit adapted for daily oral administration of Claim 16 which compnses a) a first phase of 21 daily dosage units of a progestostational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel and ethmyl estradiol at a daily dose range of from about 10 to about 35 μg, and b) a second phase of three daily dosage units of an antiprogestin of Claim 1 admimstered at a daily dose of from about 2 to 50 mg, and c) a third phase of 4 daily dosage units of an orally and pharmaceutically acceptable placebo 18 A pharmaceutically useful kit adapted for daily oral administration which comprises a) a first phase of from 18 to 21 daily dosage units, each daily dosage unit comprising a progestational agent at a daily dose equal in progestational activity to from about 35 to about 150 μg levonorgestrel and ethmyl estradiol at a daily dose range of from about 10 to about 35 μg b) a second phase of from 1 to 7 daily dose units, each daily dose unit containing an antiprogestin of Claim 1 at a concentration of from 2 to 50 mg. and ethinyl estradiol at a concentration of from about 10 to about 35 μg, and c) a third phase of from 0 to 9 daily dosage units of an orally and pharmaceutically acceptable placebo, wherein the total number of the daily dosage units in the first phase, second phase and third phase equals 28 19 A pharmaceutically useful kit adapted for daily oral administration of Claim 18 which compπses a) a first phase of 21 daily dosage units, each containing a progestational agent of this invention at a daily dose equal in progestational activity to about 35 to about 150 μg levonorgestrel and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg b) a second phase of 3 daily dose units, each daily dose umt containing an antiprogestin of Claim 1 at a concentration of from 2 to 50 mg, and ethinyl estradiol at a concentration of from about 10 to about 35 μg, and c) a third phase of 4 daily dosage units of an orally and pharmaceutically acceptable placebo

Inventors: GRUBB GARY S, JONES TODD K, MARSCHKE KEITH B, TEGLEY CHRISTOPHER M, ZHI LIN, GRUBB, GARY, S., JONES, TODD, K., MARSCHKE, KEITH, B., TEGLEY, CHRISTOPHER, M., ZHI, LIN
Applicants: AMERICAN HOME PROD, GRUBB GARY S, JONES TODD K, LIGAND PHARM INC, MARSCHKE KEITH B, TEGLEY CHRISTOPHER M, ZHI LIN, AMERICAN HOME PRODUCTS CORPORATION, GRUBB, GARY, S., JONES, TODD, K., LIGAND PHARMACEUTICALS, INC., MARSCHKE, KEITH, B., TEGLEY, CHRISTOPHER, M., ZHI, LIN
Application year: 2000
Main classification: A61P15
IPC codes: A61K31, A61K45, A61P15, C07D498